The CRM Sponsored Research Award is given out each year to outstanding Principal Investigators, clinical trials sites and the industry for their contribution in sponsored research to the nation. It is given to spur and encourage more of such efforts in the future. CRM would like to honour and acknowledge their dedication in participating in sponsored research and hope that they will keep up the good work. Congratulations to all CRM Sponsored Research Award recipients:
INVESTIGATOR & TOP RECRUITER OF THE YEAR
Dr Voon Pei Jye received the Investigator of the Year & Top Recruiter of the Year Award. For Investigator of the Year Award, he conducted the most studies that were initiated in 2018 and has the highest number of oncology trials in that year. He was also PI for 7 studies that was approved in 2018, one of which is a Phase 1, dose escalation study. He also co-authored in 3 publications in 2018 and 8 of his research findings were presented in ESMO Munich, ESMO Asia, World Conference on Lung Cancer, EndoBarcelona and Malaysia-Singapore Congress of Medicine.
For the Recruiter of the Year Award, Dr Voon has achieved first-patient-in within 100 days from site activation in 5 of his studies initiated in 2018. Four out of these 5 studies to date, have successfully reached its recruitment target.
CLINICAL TRIAL SITE OF THE YEAR
HOSPITAL PULAU PINANG
Hospital Pulau Pinang received the Clinical Trial Site of the Year Award for having conducted the highest number of sponsored research among all MOH sites. 27 sponsored research trials were conducted at this site in 2018, spanning 13 different therapeutic areas including areas of hematology, infectious disease, nephrology, gastroenterology, oncology and bioequivalence studies.
SPONSOR OF THE YEAR
Merck Sharp & Dohme (Malaysia) received the Sponsor of the Year Award for bringing in the highest number of studies that got initiated in 2018 and contributing to the highest value of sponsored research brought to the country.
CRO OF THE YEAR
IQVIA™ received the CRO of the Year Award with the highest number of studies and sites initiated in 2018 (9 studies and 22 sites), and having achieved over 71% of the total recruitment from the 22 sites activated.